Giuseppe
Emeritus
[Source: PLoS ONE, full page: (LINK). Abstract, edited.]
Open Access / Peer-Reviewed / Research Article
Protection against H5N1 Highly Pathogenic Avian and Pandemic (H1N1) 2009 Influenza Virus Infection in Cynomolgus Monkeys by an Inactivated H5N1 Whole Particle Vaccine
Misako Nakayama, Shintaro Shichinohe, Yasushi Itoh, Hirohito Ishigaki, Mitsutaka Kitano, Masahiko Arikata, Van Loi Pham, Hideaki Ishida, Naoko Kitagawa, Masatoshi Okamatsu, Yoshihiro Sakoda, Takaya Ichikawa, Hideaki Tsuchiya, Shinichiro Nakamura, Quynh Mai Le, Mutsumi Ito, Yoshihiro Kawaoka, Hiroshi Kida, Kazumasa Ogasawara
Published: December 23, 2013 / DOI: 10.1371/journal.pone.0082740
Abstract
H5N1 highly pathogenic avian influenza virus (HPAIV) infection has been reported in poultry and humans with expanding clade designations. Therefore, a vaccine that induces immunity against a broad spectrum of H5N1 viruses is preferable for pandemic preparedness. We established a second H5N1 vaccine candidate, A/duck/Hokkaido/Vac-3/2007 (Vac-3), in our virus library and examined the efficacy of inactivated whole particles of this strain against two clades of H5N1 HPAIV strains that caused severe morbidity in cynomolgus macaques. Virus propagation in vaccinated macaques infected with either of the H5N1 HPAIV strains was prevented compared with that in unvaccinated macaques. This vaccine also prevented propagation of a pandemic (H1N1) 2009 virus in macaques. In the vaccinated macaques, neutralization activity, which was mainly shown by anti-hemagglutinin antibody, against H5N1 HPAIVs in plasma was detected, but that against H1N1 virus was not detected. However, neuraminidase inhibition activity in plasma and T-lymphocyte responses in lymph nodes against H1N1 virus were detected. Therefore, cross-clade and heterosubtypic protective immunity in macaques consisted of humoral and cellular immunity induced by vaccination with Vac-3.
________
Citation: Nakayama M, Shichinohe S, Itoh Y, Ishigaki H, Kitano M, et al. (2013) Protection against H5N1 Highly Pathogenic Avian and Pandemic (H1N1) 2009 Influenza Virus Infection in Cynomolgus Monkeys by an Inactivated H5N1 Whole Particle Vaccine. PLoS ONE 8(12): e82740. doi:10.1371/journal.pone.0082740
Editor: Stefan P?hlmann, German Primate Center, Germany
Received: August 30, 2013; Accepted: October 27, 2013; Published: December 23, 2013
Copyright: ? 2013 Nakayama et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Regional Research and Development Resources Utilization Program, Japan Science and Technology Agency, the Grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan, for Joint Research Program of the Research Center for Zoonosis Control, Hokkaido University and the Japan Initiative for Global Research Network on Infectious Diseases. The funders had no role in study design, data collecton and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
-
-------
Open Access / Peer-Reviewed / Research Article
Protection against H5N1 Highly Pathogenic Avian and Pandemic (H1N1) 2009 Influenza Virus Infection in Cynomolgus Monkeys by an Inactivated H5N1 Whole Particle Vaccine
Misako Nakayama, Shintaro Shichinohe, Yasushi Itoh, Hirohito Ishigaki, Mitsutaka Kitano, Masahiko Arikata, Van Loi Pham, Hideaki Ishida, Naoko Kitagawa, Masatoshi Okamatsu, Yoshihiro Sakoda, Takaya Ichikawa, Hideaki Tsuchiya, Shinichiro Nakamura, Quynh Mai Le, Mutsumi Ito, Yoshihiro Kawaoka, Hiroshi Kida, Kazumasa Ogasawara
Published: December 23, 2013 / DOI: 10.1371/journal.pone.0082740
Abstract
H5N1 highly pathogenic avian influenza virus (HPAIV) infection has been reported in poultry and humans with expanding clade designations. Therefore, a vaccine that induces immunity against a broad spectrum of H5N1 viruses is preferable for pandemic preparedness. We established a second H5N1 vaccine candidate, A/duck/Hokkaido/Vac-3/2007 (Vac-3), in our virus library and examined the efficacy of inactivated whole particles of this strain against two clades of H5N1 HPAIV strains that caused severe morbidity in cynomolgus macaques. Virus propagation in vaccinated macaques infected with either of the H5N1 HPAIV strains was prevented compared with that in unvaccinated macaques. This vaccine also prevented propagation of a pandemic (H1N1) 2009 virus in macaques. In the vaccinated macaques, neutralization activity, which was mainly shown by anti-hemagglutinin antibody, against H5N1 HPAIVs in plasma was detected, but that against H1N1 virus was not detected. However, neuraminidase inhibition activity in plasma and T-lymphocyte responses in lymph nodes against H1N1 virus were detected. Therefore, cross-clade and heterosubtypic protective immunity in macaques consisted of humoral and cellular immunity induced by vaccination with Vac-3.
________
Citation: Nakayama M, Shichinohe S, Itoh Y, Ishigaki H, Kitano M, et al. (2013) Protection against H5N1 Highly Pathogenic Avian and Pandemic (H1N1) 2009 Influenza Virus Infection in Cynomolgus Monkeys by an Inactivated H5N1 Whole Particle Vaccine. PLoS ONE 8(12): e82740. doi:10.1371/journal.pone.0082740
Editor: Stefan P?hlmann, German Primate Center, Germany
Received: August 30, 2013; Accepted: October 27, 2013; Published: December 23, 2013
Copyright: ? 2013 Nakayama et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Regional Research and Development Resources Utilization Program, Japan Science and Technology Agency, the Grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan, for Joint Research Program of the Research Center for Zoonosis Control, Hokkaido University and the Japan Initiative for Global Research Network on Infectious Diseases. The funders had no role in study design, data collecton and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
-
-------